Pfizer and MPP Enters Licensing Agreement for COVID-19 Treatment
shot by IP News Shots / 8:28 pm on 17 November, 2021
Pfizer Inc. and Medicines Patent Pool (MPP) have declared that they signed a voluntary license agreement for Pfizer’s COVID-19 oral antiviral treatment. The agreement will allow MPP to expedite additional production and supply of the experimental antiviral. According to the agreement between Pfizer and MPP qualified generic medicine producers globally that are given sub-licenses will be able to distribute this treatment in combination with ritonavir to 95 countries, which is approximately 53% of the world’s population.
Industry: Pharmaceuticals | Type of IP: Deals - Licensing
Read more at Pfizer